We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Research · November 05, 2019

Third-Line Sunitinib Is Effective After Sequential Therapy With Cytokines and Sorafenib in mRCC

Molecular and Clinical Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Molecular and Clinical Oncology
Outcome of Third-Line Sunitinib After Sequential Therapy With Cytokines and Sorafenib in Metastatic Renal Cell Carcinoma
Mol Clin Oncol 2019 Nov 01;11(5)505-510, T Fujita, T Hirayama, M Nishi, K Matsumoto, K Yoshida, M Iwamura

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading